ArticleJournal of diabetes investigation2020
Longitudinal examination of pancreatic β-cell function in Japanese individuals.
Article in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Recent updates to understand the heterogeneity of type 2 diabetes mellitus.Journal of diabetes investigation · 2025Article
- Impaired insulin secretion and related factors in East Asian individuals.Journal of diabetes investigation · 2022Article
- Decreased serum fibroblast growth factor 19 level is a risk factor for type 1 diabetes.Annals of translational medicine · 2021Article
- Clinical evidence regarding factors linking metabolic abnormal obesity to pancreatic β-cell dysfunction.Journal of diabetes investigation · 2020Article
- Longitudinal examination of pancreatic β-cell function in Japanese individuals.Journal of diabetes investigation · 2020Article
- Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients.Diabetology & metabolic syndrome · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionWe carried out a retrospective, longitudinal analysis of β-cell function between a diabetes mellitus group, including those that progressed to diabetes mellitus during the follow-up period, and a diabetic type with glycated hemoglobin (HbA1c) <6.5 group, including those that progressed to a diabetic type during the follow-up period. β-Cell function was assessed using homeostasis model of assessment of β-cell function. MATERIALS AND
methodsThe relationship between the duration of diabetes mellitus or the diabetic type and pancreatic β-cell function was compared between the diabetes mellitus group (1,817) and diabetic type with HbA1c <6.5 group (1,843) using results from an oral glucose tolerance test. Linear mixed effects models were used to analyze repeated measurements of oral glucose tolerance tests.
resultsThe slope of the regression line of β-cell function for the duration of the diabetes mellitus group was -2.2%/year before the diagnosis. The slope differed after the diagnosis, and the difference was 1.3. The slope of the diabetic type group was -1.2%/year, and no significant difference was observed in the slope before and after the diagnosis. β-Cell function at the onset was 54.3% in the diabetic type group and 40.6% in the diabetes mellitus group, and the slope of the regression line was significantly higher in the diabetes mellitus group. We divided the diabetes mellitus and diabetic type with HbA1c <6.5 groups into obese and non-obese participants. β-Cell function declined more with obesity.
conclusionsSubsequent declines in β-cell function were faster in the diabetes mellitus group than that in the diabetic type with HbA1c <6.5 group, and increased with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.